美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

2倍做多SRPT ETF-Tradr

10.67

-1.7300-13.95%

成交量：7.49萬

成交額：81.45萬

市值：341.44萬

市盈率：- -

高：12.04

開：12.04

低：10.20

收：12.40

52周最高：29.40

52周最低：7.05

股本：32.00萬

流通股本：32.00萬

量比：0.97

換手率：23.41%

股息：- -

股息率：- -

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

美國研究綜述-Equitable Holdings、Robinhood Markets、Wingstop

ETF日報｜2倍做多Firefly Aerospace ETF升逾36%；2倍做多Arm ETF升逾32%；成長科技與貴金屬雙強

Sarepta Therapeutics股價盤前上漲3.2%，肌肉疾病藥物早中期試驗結果積極

BUZZ-肌肉疾病藥物在早中期試驗中顯示出前景，Sarepta 股價上升

Sarepta Therapeutics旗下Sirna療法在FSHD1和DM1中實現高肌肉濃度且無劑量限制性毒性

Sarepta Therapeutics：研究中多數不良事件為輕至中度且與劑量無關

Sarepta Therapeutics概念驗證數據：單劑量SRP-1001與SRP-1003可降低靶蛋白或mRNA水平

FDA確認Sarepta可提交Essence研究及真實世界證據用於新藥申請

Sarepta Therapeutics 請求與FDA會面探討提交補充新藥申請事宜

BUZZ-美國 FDA 疫苗主管普拉薩德（Vinay Prasad）辭職後，Uniqure 大幅上漲

FDA 疫苗負責人維奈-普拉薩德將於四月卸任

Sarepta Therapeutics, Inc.盤中異動股價大跌5.21%報16.54美元

Sarepta Therapeutics啓動第九屆Route 79杜氏肌營養不良症獎學金計劃申請

ETF日報｜2倍做多IONQ ETF升逾42%；三倍做多金融指數ETF漲近4%

老虎资讯综合

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/SRPU/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SRPU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SRPU\",,,,,undefined,":{"symbol":"SRPU","market":"US","secType":"STK","nameCN":"2倍做多SRPT ETF-Tradr","latestPrice":10.67,"timestamp":1774639346001,"preClose":12.4,"halted":0,"volume":74913,"delay":0,"changeRate":-0.1395161290322581,"floatShares":320000,"shares":320000,"eps":0,"marketStatus":"交易中","change":-1.73,"latestTime":"03-27 15:22:56 EDT","open":12.04,"high":12.04,"low":10.2,"amount":814458.63078,"amplitude":0.148387,"askPrice":11.05,"askSize":100,"bidPrice":10.42,"bidSize":100,"shortable":0,"etf":2,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1774641600000},"marketStatusCode":2,"adr":0,"exchange":"CBOE","adjPreClose":12.4,"sharesOutstanding":310000,"nav":15.0183,"aum":4805849.76,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":11.9738,"preClose":12.4,"latestTime":"08:00 EDT","volume":155,"amount":1900.71385,"timestamp":1774612801008,"change":-0.4262,"changeRate":-0.034371,"amplitude":0.035984},"postHourTrading":{"tag":"盘后","latestPrice":12.42,"preClose":12.4,"latestTime":"19:43 EDT","volume":1003,"amount":12483.22,"timestamp":1774568596416,"change":0.02,"changeRate":0.001613,"amplitude":0.004032},"volumeRatio":0.971257,"impliedVol":1.0728,"impliedVolPercentile":0.4038},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SRPU\",,,,,undefined,":{"symbol":"SRPU","floatShares":320000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.971257,"shares":320000,"dividePrice":0,"high":12.04,"amplitude":0.148387,"preClose":12.4,"low":10.2,"week52Low":7.05,"pbRate":"--","week52High":29.4,"institutionHeld":0,"latestPrice":10.67,"eps":0,"divideRate":0,"volume":74913,"delay":0,"ttmEps":0,"open":12.04,"prevYearClose":15.25,"prevWeekClose":8,"prevMonthClose":8.2093,"prevQuarterClose":15.25,"fiveDayClose":8,"twentyDayClose":8.2093,"sixtyDayClose":15.24},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SRPU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SRPU\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SRPU\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SRPU\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2622683457","title":"美國研究綜述-Equitable Holdings、Robinhood Markets、Wingstop","url":"https://stock-news.laohu8.com/highlight/detail?id=2622683457","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622683457?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 15:39","pubTimestamp":1774510763,"startTime":"0","endTime":"0","summary":"美国研究综述-Equitable Holdings、Robinhood Markets、Wingstop路透3月26日 - 华尔街证券分析师周四调整了对 Equitable Holdings、Robinhood Markets 和 Wingstop 等几家美国上市公司的评级和目标价。要闻 * Equitable Holdings Inc EQH.N：KBW恢复覆盖，给予 \"跑赢大盘\" 评级 * Murphy USA Inc MUSA.N：摩根大通首次覆盖，给予 \"增持\" 评级 * Robinhood Markets Inc HOOD.O：Jefferies 首次覆盖，给予买入评级 * Scotts Miracle-Gro Co SMG.N：摩根大通将其评级从 \"增持 \"下调至 \"中性\"。* Equitable Holdings Inc EQH.N：KBW恢复覆盖，评级为 \"跑赢大盘\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"37684715aaf54a73b9fe52ee56a263cc","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nL4T40E0GO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HOOD","CASY","CNO","HOYY","EQT","CTVA","TERN","TIC","TKR","HOOI","EXPI","SRPU","UNM","CRBG","IONS","PFG","GLDD","REAX","GL","CRK","SRPT","VOYA","PRU","HOII","AIR","HODU","JXN","SGI","SMG","APPF","CHWY","MET","SHW","PRI","LNC","GNW","FTDR","AFL","LMB","BRZE","PPG","PAYX","CSX","NSC","WING","MUSA","UNP","BHF","EQH","ROBN"],"gpt_icon":1},{"id":"1153818821","title":"ETF日報｜2倍做多Firefly Aerospace ETF升逾36%；2倍做多Arm ETF升逾32%；成長科技與貴金屬雙強","url":"https://stock-news.laohu8.com/highlight/detail?id=1153818821","media":"ETF追踪","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153818821?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 10:25","pubTimestamp":1774491900,"startTime":"0","endTime":"0","summary":"美股ETF涨幅Top5$2倍做多SRPT ETF-Tradr$上涨69.23%。Sarepta Therapeutics周三大涨近35%，此前该公司公布了两项治疗罕见肌肉萎缩症的初步数据。该产品两倍做多航空航天公司$Firefly Aerospace$，标的股价上行带动产品大幅走高，杠杆效应放大收益。有报道称埃隆马斯克旗下的SpaceX最快将于本周提交上市申请，周三太空概念股应声飙升，Firefly Aerospace涨超16%，Intuitive Machines涨近15%，Planet Labs涨超11%，Rocket Lab和AST SpaceMobile涨超10%。$2倍做多ARM ETF- Leverage Shares$上涨32.51%。$罗素2000指数三倍做多ETF-Direxion$上涨3.63%。债券ETF涨幅Top 5$Infracap REIT Preferred ETF$上涨1.33%。","market":"us","thumbnail":"https://static.tigerbbs.com/8fd5271ba4885dabd7633b23dfb3304b","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/8fd5271ba4885dabd7633b23dfb3304b"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"3708dfae7df7b402c74cc0c9fcc664e6","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGQ","CHAU","TAN","XPP","RKLB","TNA","AMD","ARM","UGL","YINN","RKLZ","SRPU","TLT","UYM","SPTL","ARMG","DKNG","DGP","ASTS","PL","IBB","FLYT","PFFR","NLR","FLY","LUNL","NUGT","DKNX","EDC","EMB","ASTN","DAMD","SRPT","LUNR","SMCZ","SMCI","SLV","PCY","SOXL","PLU"],"gpt_icon":0},{"id":"1106360538","title":"Sarepta Therapeutics股價盤前上漲3.2%，肌肉疾病藥物早中期試驗結果積極","url":"https://stock-news.laohu8.com/highlight/detail?id=1106360538","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1106360538?lang=zh_tw&edition=fundamental","pubTime":"2026-03-25 20:30","pubTimestamp":1774441857,"startTime":"0","endTime":"0","summary":"Sarepta Therapeutics的股价在盘前交易中上涨了3.2%，这一上涨源于其针对肌肉疾病的药物在早中期临床试验中显示出积极前景。试验数据的乐观信号提振了投资者信心，市场对该药物后续研发进展抱以期待。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SRPU","IE0002141913.USD","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","SRPT","IE0009355771.USD","BK4585","BK4139","IE00BJT1NW94.SGD"],"gpt_icon":0},{"id":"2622073060","title":"BUZZ-肌肉疾病藥物在早中期試驗中顯示出前景，Sarepta 股價上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2622073060","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622073060?lang=zh_tw&edition=fundamental","pubTime":"2026-03-25 20:18","pubTimestamp":1774441122,"startTime":"0","endTime":"0","summary":"** 公司称，这些治疗方法只需一次用药就能减少与这些疾病相关的有害蛋白质或遗传物质** 补充说大多数副作用为轻度至中度，没有剂量限制性安全信号** 2025 年股价下跌约 82%(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"22d97c574d1b8881ace253d280e1b6b5","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nL4S40D14K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0002141913.USD","BK4585","IE00B2B36J28.USD","IE0009355771.USD","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","SRPT","SRPU","BK4139"],"gpt_icon":0},{"id":"1104289809","title":"Sarepta Therapeutics旗下Sirna療法在FSHD1和DM1中實現高肌肉濃度且無劑量限制性毒性","url":"https://stock-news.laohu8.com/highlight/detail?id=1104289809","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1104289809?lang=zh_tw&edition=fundamental","pubTime":"2026-03-25 20:07","pubTimestamp":1774440435,"startTime":"0","endTime":"0","summary":"Sarepta Therapeutics公司宣布，其Sirna疗法在针对面肩肱型肌营养不良症1型（FSHD1）和强直性肌营养不良1型（DM1）的研究中取得重要进展。该疗法在肌肉组织中达到了高浓度分布，同时未出现剂量限制性毒性反应。\n这一突破性成果为两种罕见肌肉疾病的治疗开辟了新途径。高肌肉靶向性结合良好的安全性特征，预示着Sirna疗法在神经肌肉疾病领域具有广阔的应用前景。\n研究人员指出，该结果支持进一步推进临床开发计划。下一步将重点评估其长期疗效与安全性表现。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SRPT","SRPU","IE0002141913.USD","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","IE00BFTCPJ56.SGD","IE0009355771.USD","IE00BJT1NW94.SGD","BK4585","BK4139"],"gpt_icon":0},{"id":"1161884966","title":"Sarepta Therapeutics：研究中多數不良事件為輕至中度且與劑量無關","url":"https://stock-news.laohu8.com/highlight/detail?id=1161884966","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161884966?lang=zh_tw&edition=fundamental","pubTime":"2026-03-25 20:06","pubTimestamp":1774440394,"startTime":"0","endTime":"0","summary":"在Sarepta Therapeutics进行的研究中，所观察到的不良事件大多呈现轻度至中度表现，且未显示出剂量依赖性特征。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00B2B36J28.USD","IE0002141913.USD","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","SRPT","IE0009355771.USD","SRPU","IE00BJJMRZ35.SGD","BK4585"],"gpt_icon":0},{"id":"1193886488","title":"Sarepta Therapeutics概念驗證數據：單劑量SRP-1001與SRP-1003可降低靶蛋白或mRNA水平","url":"https://stock-news.laohu8.com/highlight/detail?id=1193886488","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1193886488?lang=zh_tw&edition=fundamental","pubTime":"2026-03-25 20:06","pubTimestamp":1774440383,"startTime":"0","endTime":"0","summary":"最新概念验证研究数据显示，Sarepta Therapeutics研发的SRP-1001和SRP-1003在单次给药后，能有效降低目标蛋白或信使核糖核酸（mRNA）的表达水平。这一突破性进展为相关疗法的后续开发奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"22d97c574d1b8881ace253d280e1b6b5","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009355771.USD","SRPT","IE00BFTCPJ56.SGD","SRPU","IE00BJJMRZ35.SGD","IE0002141913.USD","BK4139","IE00BJT1NW94.SGD","IE00B2B36J28.USD","BK4585"],"gpt_icon":0},{"id":"1100608630","title":"FDA確認Sarepta可提交Essence研究及真實世界證據用於新藥申請","url":"https://stock-news.laohu8.com/highlight/detail?id=1100608630","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100608630?lang=zh_tw&edition=fundamental","pubTime":"2026-03-19 20:32","pubTimestamp":1773923522,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局已正式批准Sarepta Therapeutics公司提交其Essence临床研究数据及真实世界证据，作为支持新药申请的关键材料。这一决定为Sarepta推进相关疗法审批流程扫清了重要障碍。FDA的认可标志着监管机构对创新证据采集方式的开放性态度，也为生物技术行业树立了新的审评标准。公司表示将按计划提交完整数据包，并与FDA保持密切沟通以推进后续流程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009355771.USD","BK4585","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","IE00B2B36J28.USD","BK4139","IE0002141913.USD","IE00BJJMRZ35.SGD","SRPU","SRPT"],"gpt_icon":0},{"id":"1111209231","title":"Sarepta Therapeutics 請求與FDA會面 探討提交補充新藥申請事宜","url":"https://stock-news.laohu8.com/highlight/detail?id=1111209231","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111209231?lang=zh_tw&edition=fundamental","pubTime":"2026-03-19 20:31","pubTimestamp":1773923518,"startTime":"0","endTime":"0","summary":"Sarepta Therapeutics Inc. 已正式向美国食品药品监督管理局（FDA）提出会面请求，旨在讨论提交补充新药申请（sNDA）的相关事宜。此次会议将聚焦于新药申请材料的准备与提交策略。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJJMRZ35.SGD","IE00B2B36J28.USD","BK4585","IE00BJT1NW94.SGD","SRPT","IE0009355771.USD","SRPU","IE00BFTCPJ56.SGD","IE0002141913.USD","BK4139"],"gpt_icon":0},{"id":"2617655464","title":"BUZZ-美國 FDA 疫苗主管 普拉薩德（Vinay Prasad）辭職後，Uniqure 大幅上漲","url":"https://stock-news.laohu8.com/highlight/detail?id=2617655464","media":"路透中文","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617655464?lang=zh_tw&edition=fundamental","pubTime":"2026-03-07 07:19","pubTimestamp":1772839152,"startTime":"0","endTime":"0","summary":"3月6日 - ** 在美国上市的荷兰制药商UniQure UQ1.F、QURE.O的股票在延时交易中上涨61%，至22.95美元** 美国食品和药物管理局疫苗和生物制品部门负责人普拉萨德博士将于4月底离职 ，FDA局长马卡里周五表示** 最近，普拉萨德在 FDA 的部门与荷兰制药商 UniQure 就其亨廷顿氏症基因疗法问题陷入反复争执 。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nL4T3ZU24A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","SRPT","BK4585","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","IE00B2B36J28.USD","QURE","CAPR","SLDB","SRPU","IE00BJJMRZ35.SGD","TSHA","IE0009355771.USD","LU0109394709.USD","BK4139","IE0002141913.USD","LU0320765992.SGD"],"gpt_icon":0},{"id":"2617265309","title":"FDA 疫苗負責人維奈-普拉薩德將於四月卸任","url":"https://stock-news.laohu8.com/highlight/detail?id=2617265309","media":"路透中文","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617265309?lang=zh_tw&edition=fundamental","pubTime":"2026-03-07 06:20","pubTimestamp":1772835654,"startTime":"0","endTime":"0","summary":"更新 2-FDA 疫苗负责人维奈-普拉萨德将于四月卸任增加背景介绍路透3月6日 - 美国卫生与公众服务部发言人周五表示，美国食品和药物管理局疫苗与生物制品部门负责人维奈-普拉萨德博士将于4月底离职。普拉萨德是一位肿瘤学家，在加入该机构之前曾对美国的药品和疫苗政策提出过直言不讳的批评，他曾因几项监管决定而引起争议。去年 5 月，他被任命为 FDA 生物制品评估与研究中心主任。HHS 指责该公司在监管机构的要求方面误导了公众。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nL4T3ZU22P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BFTCPJ56.SGD","IE00B2B36J28.USD","IE0002141913.USD","SRPU","IE0009355771.USD","IE00BJT1NW94.SGD","BK4139","BK4585","IE00BJJMRZ35.SGD","SRPT"],"gpt_icon":0},{"id":"2614962868","title":"Sarepta Therapeutics, Inc.盤中異動 股價大跌5.21%報16.54美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2614962868","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614962868?lang=zh_tw&edition=fundamental","pubTime":"2026-02-28 03:15","pubTimestamp":1772219710,"startTime":"0","endTime":"0","summary":"北京时间2026年02月28日03时15分，Sarepta Therapeutics, Inc.股票出现波动，股价大幅下跌5.21%。截至发稿，该股报16.54美元/股，成交量134.941万股，换手率1.29%，振幅3.90%。Sarepta Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为1.08%。Sarepta Therapeutics, Inc.公司简介：Sarepta Therapeutics公司是一家专注于治疗罕见、传染病和其他疾病的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260228031510a727cf58&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260228031510a727cf58&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE0002141913.USD","SRPU","IE00B2B36J28.USD","IE00BJT1NW94.SGD","SRPT","IE00BFTCPJ56.SGD","BK4139","IE00BJJMRZ35.SGD","IE0009355771.USD","BK4585","LENZ","BK4007","BK4539"],"gpt_icon":0},{"id":"1127234068","title":"Sarepta Therapeutics啓動第九屆Route 79杜氏肌營養不良症獎學金計劃申請","url":"https://stock-news.laohu8.com/highlight/detail?id=1127234068","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1127234068?lang=zh_tw&edition=fundamental","pubTime":"2026-02-27 22:01","pubTimestamp":1772200874,"startTime":"0","endTime":"0","summary":"Sarepta Therapeutics宣布正式开放第九届Route 79杜氏肌营养不良症奖学金项目的申请通道。该项目旨在为受杜氏肌营养不良症影响的杰出学生提供教育支持，助力其追求学术与职业发展梦想。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SRPT","IE0009355771.USD","SRPU","IE00BJT1NW94.SGD","BK4139","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","BK4585","IE0002141913.USD"],"gpt_icon":0},{"id":"1153249938","title":"ETF日報｜2倍做多IONQ ETF升逾42%；三倍做多金融指數ETF漲近4%","url":"https://stock-news.laohu8.com/highlight/detail?id=1153249938","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153249938?lang=zh_tw&edition=fundamental","pubTime":"2026-02-27 08:43","pubTimestamp":1772153022,"startTime":"0","endTime":"0","summary":"美股ETF涨幅Top5$2倍做多IONQ ETF-Defiance$上涨42.35%。$2倍做空IONQ ETF-Defiance$下跌43.30%。该产品三倍做空富时中国指数，相关多头产品走弱带动其逆向上涨。该产品三倍做空纳斯达克指数，因纳斯达克指数当日回落，反向杠杆产品获得涨幅。大宗商品ETF涨幅Top 5$二倍做多黄金矿业指数ETF-Direxion$上涨5.08%。该产品跟踪小市值黄金矿业公司，相关成分股普遍上行带动ETF上涨。行业指数ETF涨幅Top 5$金融指数ETF-Direxion三倍做多罗素金融股$上涨3.80%。$两倍做多金融股ETF-ProShares$上涨2.49%。","market":"us","thumbnail":"https://static.tigerbbs.com/8fd5271ba4885dabd7633b23dfb3304b","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/8fd5271ba4885dabd7633b23dfb3304b"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"82fa76947202ea24bcb109b846bea089","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONQ","KIE","UYG","IONL","OPEN","BK4535","FXP","FAS","QID","IONX","DRN","NUGT","BK4591","OPEX","IYT","GDXJ","TXXS","AGQ","YANG","EOSU","TLT","EOSE","GDX","UGL","LUNL","SQQQ","SRPU","PFFR","BK4550","IONZ","BK4585","BK4588","NU","RDWU","YXI","BK4170","LUNR","SRPT","VMBS","BK4504","NUG","BK4602","RDW","TIP"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":14,"code":"91000000","status":"200"}]}}